

Department of Internal Medicine  
F NUK 104, University Hospital  
Zürich, Rämistrasse 100, 8091  
Zürich, Switzerland

Katarina Hostanska, Reinhard  
Saller

Department of Medicine,  
Bioforce AG, Grünastrasse, 9325  
Roggwil, Switzerland

Silvia Bommer, Michel Weber

Department of Research and  
Development, Bioforce AG,  
Grünastrasse, 9325 Roggwil,  
Switzerland

Blerim Krasniqi

**Correspondence:** K. Hostanska,  
University Hospital Zürich,  
Dept. of Internal Medicine F NUK  
104, Rämistrasse 100, 8091  
Zürich, Switzerland. E-mail:  
katarina.hostanska@access.unizh.ch

**Acknowledgement and funding:**  
This work was supported by  
Bioforce AG (Roggwil,  
Switzerland). Thanks are due  
to Schwabe Arzneimittel  
(Karlsruhe, Germany) for  
supplying us with hyperforin and  
Prof. Dr J. Reichling (Heidelberg,  
Germany) for helpful discussion  
and comments on manuscript.  
The authors gratefully  
acknowledge Dr Joyce Baumann  
for linguistically improving the  
manuscript.

## Comparison of the growth-inhibitory effect of *Hypericum perforatum* L. extracts, differing in the concentration of phloroglucinols and flavonoids, on leukaemia cells

Katarina Hostanska, Silvia Bommer, Michel Weber, Blerim Krasniqi  
and Reinhard Saller

### Abstract

In this study we compared, simultaneously, the growth-inhibitory effect of *Hypericum perforatum* L. extracts, containing various amounts of hyperforin (A 3.25%; B 2.21%; C 0.21% w/w) and flavonoids (A and B 5.3%; C 10% w/w), but closely same amounts of naphthodiantrones (0.3%) on two leukaemic cell lines K562 and U937 in the WST-1 assay. The GI50 (concentration of extracts which caused 50% of cell growth inhibition) for *H. perforatum* extracts analysed and characterized by HPLC for their biologically active constituents was 248.3–621.3  $\mu\text{g mL}^{-1}$  in K562 and 378.2–911.7  $\mu\text{g mL}^{-1}$  in U937 cells. The corresponding values of the three main groups were 1.6–3.9  $\mu\text{M}$  naphthodiantrones, 1.0–40.7  $\mu\text{M}$  phloroglucinols and 30.5–68.5  $\mu\text{M}$  flavonoids. The results of this study supported the hypothesis that, apart from hyperforin and flavonoids, other components of the extract could be involved in its growth-inhibitory effect that it exerts without light activation.

### Introduction

Crude extracts of *Hypericum perforatum* L. (Clusiaceae) contain a wide range of compounds with pharmacological properties, such as naphthodiantrones, phloroglucinols, xanthenes, proanthocyanidines, biflavones, flavonol derivatives, phenylpropanes, essential oils and amino acids (Bombardelli & Morazzoni 1995). Hypericin, a component of *H. perforatum* extracts, exhibits light-dependent phototoxicity on the growth of various human malignant cells (Miccoli et al 1998; Lavie et al 1999) and there are also numerous studies on the antiproliferative effects of flavonoids (quercetin) in malignant cells (Uddin & Choudhry 1995; Kang & Liang 1997). The acylphloro-glucinol derivative hyperforin is the major non-nitrogenous secondary metabolite of *H. perforatum*. Apart from its characterized antibacterial properties (Gurevich et al 1971), it was found that hyperforin exerted inhibitory effects on human epidermal cells and on the proliferation of phytohaemagglutinin-stimulated peripheral blood mononuclear cells. In addition, it inhibited the growth of autologous MT-450 breast carcinoma in Wistar rats in-vivo (Schempp et al 2000, 2002). Recently, was reported that an *H. perforatum* extract exerted growth-inhibitory activity on leukaemic (K562, U937) cells, human glioblastoma LN229 and normal brain astrocytes (Hostanska et al 2002).

The aim of this study was to investigate this activity in relation to the quantity of the metabolite hyperforin in extracts. Light-dependence was examined under exposure to 7.5  $\text{J cm}^{-2}$  white light using hypericin as a phototoxic control. This paper describes the cell growth-inhibitory data of alcoholic hypericum extracts, which suggested that hyperforin and flavonoids are not the only active antiproliferative components of the extract but that other constituents of extract might modulate its efficacy.

## Materials and Methods

### Reagents

Hypericin ( $C_{30}H_{16}O_8$ ), quercetin ( $C_{15}H_{10}O_7 \cdot 2H_2O$ ), rutin ( $C_{27}H_{30}O_{16} \cdot 3H_2O$ ) and etoposide were from Alexis Corporation, Lausen, Switzerland. Hyperforin ( $C_{35}H_{52}O_4$ ) was isolated and purchased from Natural Product Department of Dr W. Schwabe GmbH & Co. (Karlsruhe, Germany) as previously described by Erdelmeier (1998). The isolated hyperforin fraction yielded about 18% adhyperforin, identified as a homologue of hyperforin (Maisenbacher & Kovar 1992) and characterized by spectroscopic methods (Rücker et al 1995). Reagents were dissolved in dimethyl sulfoxide (DMSO) and stored at  $-20^\circ\text{C}$  in samples exclusive of hyperforin, which was stored at  $-80^\circ\text{C}$ . Acetonitrile, methanol, tetrahydrofuran and 85% phosphoric acid from Sigma (Buchs, Switzerland) and Milli-Qplus purified water were used as solvents for chromatography.

Cell proliferation reagent WST-1 was purchased from Roche Diagnostica (Rotkreuz, Switzerland).

### Extracts

The *H. perforatum* extracts (A-908661; B-F7626; C-813400) were supplied and analysed by Research Department of Bioforce AG (Roggwil, Switzerland). Only A was a commercially produced extract; B and C were experimental extracts. *H. perforatum* extract A was prepared by ethanol-water maceration of fresh flowering tops (15–20 cm), extract B was obtained by maceration of flowering tops dried in the dark and extract C by aqueous-ethanolic percolation of the light-dried whole aerial parts of the plants (including leaves and stems) followed by processing to dry extract. The drug-extract ratio was 1.3–1.7:1. Extracts A and B were derived from the same harvested herb mixture, equally processed, differing only in the kind of herb material macerated. Extract A was prepared from fresh herb mixture and B from one dried at  $40^\circ\text{C}$  in the dark, and were stored in the dark during extraction. Further, the macerates A and B were concentrated under vacuum fluid extraction to viscid fluid. The extracts were adjusted to a final ethanol concentration of about 30%. However, extract C, after adjusting the concentration of hypericin to 0.3%, was processed to brown powder by spray drying.

### High-performance liquid chromatography (HPLC) conditions

Aqueous alcoholic extracts of *H. perforatum* were analysed by HPLC coupled simultaneously to UV diode array detector (Brolis et al 1998) and the individual constituents of the three main groups (naphthodianthrones, phloroglucinols, flavonoids) were quantified using external reference standards. Analyses of extracts were performed on reversed-phase columns (RP-18). The analyses were for a 20–40 min period at a flow rate of

$0.8\text{ mL min}^{-1}$ . The injected volume of the samples was  $20\ \mu\text{L}$ . Chromatographic separation of flavonol glycosides (rutin, hyperosid, isoquercitrin, quercitrin), flavonol aglycone (quercetin), biflavones (I3,I18-biapiogenin, I3',I18-biapiogenin) and naphthodianthrones (hypericin, pseudohypericin) was carried out using a gradient consisting of an acidic phosphate buffer and an eluent mixture of acetonitrile, methanol and tetrahydrofuran buffered with phosphoric acid. The wavelengths of the diode array detector were set at 360 nm (flavonols) and 590 nm (naphthodianthrones). The same concentration ( $0.8\text{ mg mL}^{-1}$ ) of the extracts A, B and C was used for the flavonoids and naphthodianthrones quantification. The phloroglucinols were extracted with ethanol under exclusion of light and detected at 270 nm. Separation was carried out using solvents (A, acetonitrile; B, acidic phosphate buffer). The injected concentrations were  $16\ \mu\text{g}$  (extract A and B) and  $132\ \mu\text{g}$  (extract C) by the analysis of phloroglucinols content. Calibration curves were obtained by employing external reference standards: hypericin for naphthodianthrones, rutin for flavonoids and an external working standard for phloroglucinols (hyperforin is not commercially available). Integrated peak areas were plotted against the corresponding amount of the injected standards. The chromatographic data were recorded and processed by HP Chemstation and PE Turbochrom software.

### Culture conditions and cell growth assay

To determine the cytotoxicity of the extracts, human leukaemia K562 and U937 cells from the American Type Culture Collection (Rockville, MD) were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mm L-glutamine and 1% penicillin-streptomycin (Sigma), in a 5%  $\text{CO}_2$ , 95% air fully humidified atmosphere at  $37^\circ\text{C}$ . The assay medium was 1640 RPMI supplemented with 2% FCS. Cell proliferation was indirectly measured by a colorimetric assay based on the cleavage of the tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2 H-5-tetrazolio]-1,3-benzene disulfonate) to formazan by mitochondrial dehydrogenases in viable cells (Ishiyama et al 1996). Cytotoxicity of extracts, hypericin, hyperforin and flavonoids (rutin, quercetin) were determined simultaneously using WST-1 agent after exposure of  $5 \times 10^3$  cells to various concentrations of the test substances in the dark or after the  $7.5\text{ J cm}^{-2}$  light irradiation (20 cm distance from 75 W tungsten lamp over 10 min) for 48 h (Miccoli et al 1998). The absorbance of the samples against a background control as blank using a microtitre plate (ELISA) reader at 450 nm wavelength was measured. The reference wavelength was 650 nm. Six independent sets of experiments performed in triplicate were evaluated. *H. perforatum* extracts were dissolved in a mixture of DMSO and ethanol (1:1). Controls with the solvent DMSO and ethanol below 0.2% were tested in parallel. The growth inhibition rate was calculated as percentage of untreated controls and did not affect the cell growth. Extracts were compared using the GI50 value, the

concentration of individual compounds reducing cell growth by 50%. GI50 values were obtained from each dose–response curve by linear regression analysis of data using the Microsoft Excel software.

### Statistical analysis

The exerted growth-inhibitory effect expressed as GI50 of three *H. perforatum* extracts in the dark and under  $7.5 \text{ J cm}^{-2}$  white light were compared using a one-way analysis of variance followed by paired comparisons of the concentration values GI50 with Newman–Keuls post-hoc test. Six independent experiments performed in triplicates were analysed for the differences between individual extracts and treatments. The type I error rate was set at 0.05 for all analyses. Probability values equal to or less than 0.05 were considered to be statistically significant.

## Results and Discussion

### HPLC analysis of the individual compounds of *H. perforatum* extracts




Before testing the extracts in the biological system, they were analysed by HPLC and the individual flavonoids, naphthodianthrones and phloroglucinols were quantified. The results are shown in Table 1 and representative chromatograms of the three main groups of *H. perforatum* extract A and C are presented in Figure 1. Concerning the amount of naphthodianthrones, there was only a small alteration (0.21–0.32% w/w). We chose the three different *H. perforatum* extracts mainly on the basis of their differences in phloroglucinol content (A 3.25%; B 2.21%; C 0.21% w/w). The negligible concentration of hyperforin in extract C was due to the processing, in which chloro-


phyll was also precipitated with hyperforin. In addition, the flavonoid content in extract C was about 10% compared with extracts A and B, which contained 5%. Analyses of the individual flavonoids showed that the most abundant flavonoids in extracts A and B were hyperoside/isoquercitrin (1%) and quercetin (2.8–3.1%). In extract C hyperoside/isoquercitrin (4.2%) and rutin (3.4%) dominated. However, extracts A (2.8%) and B (3.1%) were richer in quercetin than extract C (0.72%). The high amount of quercetin in both extract A and B could be related to the extraction procedure by which flavanol glycosides degrade to quercetin. There were differences in the contents of, for us, unknown (x, y, u) flavonoids between the extracts A (0.3%) and B (0.2%) and extract C (1.1%). According to newly described phenolic compounds of the *H. perforatum* extract (Jürgenliemk & Nahrstedt 2002), they could be possibly identified as the flavonoids miquelianin, astilbin and quercetin-3-O-(2''-O-acetyl)- $\beta$ -D-galactoside. We examined the *H. perforatum* extracts prepared from the aerial part of herbs, because the individual chemical constituents investigated in this study accumulate predominantly in the flowers, stems and leaves. Hyperforin occurs only in the reproductive parts of the plant (flowers, ripe fruits). The amount of constituents in the extract depends on the quantity of each part in the processing mixture, harvest time and extraction procedure (Meier 1999; Tekelova et al 2000). Recently, the highest percentages of hyperforin and its derivatives were found in extracts obtained from fresh samples with significantly lower amounts of these derivatives being detected in air-dried samples. The content of hyperforin in samples obtained by light-extraction was diminished to a negligible content (Bergonzi et al 2001). Our HPLC analysis of hypericum extracts produced by maceration of fresh and dried herbs was in accordance with the aforementioned findings. The amount of hyperforin in extract B (derived from dried flowering tops) was reduced

**Table 1** HPLC analysis of *Hypericum perforatum* L. extracts.

Constituents	A-908661 (mg/100 g)	B-F7626 (mg/100 g)	C-813400 (mg/100 g)
Rutin	585.0	655.0	3357.0
Hyperoside/isoquercitrin	1080.0	1003.0	4228.0
Flavonoid x	210.0	137.0	651.0
Flavonoid y	110.0	30.0	315.0
Quercitrin	204.0	141.0	447.0
Flavonoid u	0.0	49.0	154.0
Quercetin	2794.0	3146.0	715.0
Biapigenin	310.0	187.0	219.0
Flavonoids	5294.0	5349.0	10085.0
Pseudohypericin	235.6	177.1	270.1
Hypericin	41.8	35.9	47.5
Naphthodianthrones	277.4	213.0	317.5
Hyperforin	2772.0	1901.0	181.0
Adhyperforin	481.1	314.0	29.5
Phloroglucinols	3253.1	2215.0	210.4

Naphthodianthrones are expressed as hypericin (MW 504.4), phloroglucinols as hyperforin (MW 536.8) and flavonoids as rutin  $3\text{H}_2\text{O}$  (MW 664.5).





**Figure 1** Chromatograms of the *H. perforatum* extracts A-908661 (A–C) and C-813400 (D–E) after separation of naphthodianthrones, phloroglucinols and flavonoids on RP-18 column. In A and D the HPLC profiles of the flavonoid compounds of extracts at 360 nm are shown. Peaks are assigned as 1 = rutin, 2 = hyperoside/isoquercitrin, 3 = x, 4 = y, 5 = quercitrin, 6 = u, 7 = quercetin, 8 = I 3, II 8-biapigenin (x, y and u are components not known to us). HPLC profiles of the naphthodianthranoid compounds of *H. perforatum* extracts detected at 590 nm with peaks 1 = pseudohypericin and 2 = hypericin are shown in B and E. HPLC profiles of phloroglucinols at 270 nm wavelength are presented in C and F. Peaks are assigned as 1 and 4 = hyperforin, 2 and 5 = adhyperforin (C and F, respectively) and 1, 2, 3 for the components not known to us (F). The injected concentrations of the extracts A, B and C for the phloroglucinols analysis were 16  $\mu\text{g}$  (extracts A, B) and 132  $\mu\text{g}$  (extract C).

by 33% compared with its content in extract A (from fresh flowering tops) and in extract C (from light-dried herbs) its content was only 0.2%. There were differences in the chromatograms of phloroglucinols between extract C compared with extracts A and B. Phloroglucinols from extracts A or B included only hyperforin and adhyperforin (peaks 1 and 2; Figure 1C). However, on the chromatogram of extract C, further peaks (1, 2 and 3, Figure 1F) were detected. They could be possibly identified as other phloroglucinols (e.g. furohyperforin and oxyhyperforin), as recently reported (Bergonzi et al 2001). Due to the instability of hyperforin and its tendency to degradation it must be protected from oxidation (Orth et al 1999). Despite its instability, hyperforin is an orally bioavailable component and is present in the plasma of blood samples from subjects after administration of clinically tested hypericum extracts for therapeutic purposes (Biber et al 1998; Chi & Franklin 1999).

### Comparison of the antiproliferative effects of *H. perforatum* extracts

We compared the growth-inhibitory effects of extracts in the dark and under the  $7.5 \text{ J cm}^{-2}$  white light exposure by haematological cell lines (K562, U937) after 48 h,

which responded well to the *H. perforatum* extract in our previous study (Hostanska et al 2002). Growth-inhibitory concentrations 50% (GI50) were evaluated from each individual dose–response curve of all three extracts, A, B and C, simultaneously performed in triplicate and repeated six times. In parallel, the inhibitory activity of rutin and quercetin (Csokay et al 1997; Rong et al 2000), two flavonoid constituents of the extracts, hyperforin and that of phototoxic hypericin (Miccoli et al 1998; Lavie et al 1999) were also investigated. The cytotoxicity of different types of flavonoids showed great variation in their GI50 concentration within the same cell line, and in relation to distinct cell types (Kang & Liang 1997; Cos et al 2001). Quercetin had a more pronounced effect on leukaemia cells than rutin, as shown by the GI50 values, which differed by a factor of ten on the logarithmic scale. At a concentration of approximately  $15 \mu\text{M}$  hyperforin, the growth of both leukaemia cells was reduced by 50%. Light-activated hypericin showed a strong inhibitory effect in contrast to its low effect in the dark. The cytotoxic drug etoposide was used as a positive control in the cytotoxicity assay (Jia et al 2001) and the GI50 concentration for etoposide was found to be  $5.8 \mu\text{M}$  and  $0.63 \mu\text{M}$  for K562 and U937 cells after 48 h of treatment. The GI50

**Table 2** GI50 values of *H. perforatum* constituents in native extracts and of isolated components in leukaemic cell lines.


	K562	U937
Native extract <sup>a</sup>		
A	406.7 ± 50.2	672.5 ± 101.6
B	621.3 ± 113	911.7 ± 143.2
C	248.3 ± 19.4	378.2 ± 43.2
Hypericin <sup>b</sup>		
A	2.2 ± 0.3	3.7 ± 0.5
B	2.6 ± 0.5	3.9 ± 0.6
C	1.6 ± 0.1	2.4 ± 0.3
Hyperforin <sup>b</sup>		
A	24.6 ± 3.0	40.7 ± 5.9
B	25.6 ± 4.7	37.5 ± 5.9
C	1.0 ± 0.1	1.5 ± 0.2
Rutin 3H <sub>2</sub> O <sup>b</sup>		
A	3.6 ± 0.4	5.9 ± 0.9
B	6.1 ± 1.1	10.0 ± 1.4
C	12.5 ± 1.0	19.1 ± 2.2
Quercetin <sup>b</sup>		
A	37.6 ± 4.6	62.2 ± 9.4
B	64.7 ± 11.8	94.9 ± 14.9
C	5.9 ± 0.5	8.9 ± 1.0
Hypericin <sup>c</sup>	37.5 ± 6.3 <sup>d</sup>	21.0 ± 2.8 <sup>d</sup>
	1.2 ± 0.2 <sup>e</sup>	1.0 ± 0.1 <sup>e</sup>
Hyperforin <sup>c</sup>	14.2 ± 2.5	15.3 ± 2.1
Rutin 3H <sub>2</sub> O <sup>c</sup>	126.4 ± 16.8	161.5 ± 8.1
Quercetin <sup>c</sup>	28.4 ± 1.96	36.3 ± 4.1
Etoposide	5.8 ± 0.6	0.63 ± 0.1

Data are means ± s.d. <sup>a</sup>Mean concentration values of individual *H. perforatum* extracts ( $\mu\text{g mL}^{-1}$ ).

<sup>b</sup>Corresponding mean concentration values of single constituents in *H. perforatum* extracts ( $\mu\text{M}$ ).

<sup>c</sup>Mean concentration values of commercially available compounds ( $\mu\text{M}$ ). <sup>d</sup>Experiments in the dark.

<sup>e</sup>Experiments under  $7.5 \text{ J cm}^{-2}$  white light.



**Figure 2** In-vitro growth-inhibitory activity of individual *H. perforatum* extracts investigated in darkness (A) or under  $7.5 \text{ J cm}^{-2}$  light activation (B) in leukaemia cell lines K562 and U937. Vertical bars represent means  $\pm$  s.d. of GI50 from six independent experiments. The statistical evaluation of differences between columns are indicated (\* $P < 0.001$ , one-way analysis of variance).

values of single compounds are summarized in Table 2. The comparison of GI50 values of individual extracts (Figure 2) showed that there are significant differences in the growth-inhibitory activity between extracts A and B ( $P < 0.001$ , K562; U937), between B and C ( $P < 0.001$ , K562; U937) and further between A and C ( $P < 0.001$ , K562; U937) without light exposure. The individual GI50 values ( $\mu\text{g mL}^{-1}$ ) of extracts A, B and C were 406.7, 621.3 and 248.3, respectively, for K562 and 672.5, 911.7 and 378.2 for U937 cells. The corresponding values of the three main groups were 1.6–3.9  $\mu\text{M}$  naphthodianthrones, 1.0–40.7  $\mu\text{M}$  phloroglucinols and 30.5–68.5  $\mu\text{M}$  flavonoids (calculated as rutin). The phototoxicity of *H. perforatum* extract C on both tumour cell lines (162.4  $\mu\text{g mL}^{-1}$  in K562; 150.8  $\mu\text{g mL}^{-1}$  in U937) differs significantly ( $P < 0.001$ ) from that of A (281.5  $\mu\text{g mL}^{-1}$ , for K562; 453.3  $\mu\text{g mL}^{-1}$ , for U937) and B (365.1  $\mu\text{g mL}^{-1}$ , for K562; 522.5  $\mu\text{g mL}^{-1}$ , for U937) after light exposure. The corresponding calculated concentrations of components hypericin, hyperforin, rutin and quercetin to GI50 values of individual native extracts are summarized in

Table 2. The growth-inhibitory effects and the differences that extract A and B exert without light activation could be explained by their different hyperforin concentration. The GI50 values of hyperforin in the extracts (24–40  $\mu\text{M}$ ) were in a comparable range to the GI50 values of single isolated constituent (15  $\mu\text{M}$ ). Both extracts have closely comparable concentrations of the further two main groups of constituents, naphthodianthrones and flavonoids. The flavonoid pattern was similar, because the same herbal mixture and production procedure were employed. In addition, the GI50 values of quercetin in extracts A and B (17.2–42.8  $\mu\text{M}$ ) were in accordance with the values found for isolated flavonoid (28.4–36.3  $\mu\text{M}$ ). Since hypericum extract C, with the lowest concentration of hyperforin, showed most activity in the same experiments and the corresponding GI50 values of flavonoids quercetin and rutin in the extract were several times lower than that established for isolated substances, the possibility cannot be disregarded that the observed activity was modulated by other component(s) (e.g. procyanidin B2, our unpublished data). The biflavones (Silva et al 1995) and phenylpropanes (chlorogenic and caffeic acids) also showed antiproliferative efficacy toward various malignant cells (Zheng et al 1995; Nagao et al 2001). In addition, the cooperation between individual components of the extract cannot be ruled out. It was reported that the solubility of hypericin was enhanced in the presence of the dimeric procyanidin B2, a constituent of the tannin fraction of *H. perforatum* extract, which influenced the antidepressant activity exerted in the forced swimming test (Butterweck et al 1998). Recently, it has been shown that the flavonoid rutin is essential for the antidepressant activity of *H. perforatum* extract (Noldner & Schotz 2002) and that quercetin effectively reduces the toxicity of hypericin (Mirossay et al 2001; Wilhelm et al 2001). Under light exposure, the phototoxicity of the constituent hypericin was decisive, and being in the concentration range of 1–2.5  $\mu\text{M}$  was in accordance with published findings (Lavie et al 1999). However, quercetin at a concentration of  $10^{-5} \text{ M}$  exerted a protective effect on hypericin-induced cytotoxicity in leukaemia HL-60 cells (Mirossay et al 2001). Lower concentrations of quercetin had no protective effect. The higher potency of extract C (low quercetin content) in comparison with extract A and B (high amount of quercetin) can at least be explained in the light of this finding.

## Conclusion

In this study, we showed differences in the antiproliferative activity of *H. perforatum* extracts, which differ in the concentration of their two main groups of constituents, namely hyperforins and flavonoids. *H. perforatum* extract contains a number of pharmacologically active constituents, which individually (or in interaction with each other) may potentially participate in its exerted effect. The antiproliferative effect of *H. perforatum* extract cannot be fully explained by its two main pharmacological constituents, hypericin and hyperforin, as flavonoids at least also contribute to this action. To what extent individual substances

and their combination contribute to the documented growth-inhibitory effect of *H. perforatum* extracts on leukaemia cells (K562, U937) remains the subject of our current investigations.

## References

- Bergonzi, M. C., Bilia, A. R., Gallori, S., Guerrini, D., Vincieri, F. F. (2001) Variability in the content of the constituents of *Hypericum perforatum* L. and some commercial extracts. *Drug. Dev. Ind. Pharm.* 27: 491–497
- Biber, A., Fischer, H., Roemer A., Chatterjee, S. S. (1998) Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. *Pharmacopsychiatry* 31 (Suppl.): 36–43
- Bombardelli, E., Morazzoni, P. (1995) *Hypericum perforatum*. *Fitoterapia* 66: 43–68
- Brolis, M., Gabetta, B., Fuzzati, N., Pace, R., Panzeri, F., Peterlongo, F. (1998) Identification by high-performance liquid chromatography-diode array detection-mass spectrometry and quantification by high-performance liquid chromatography-UV absorbance detection of active constituents of *Hypericum perforatum*. *J. Chromatogr. A* 825: 9–16
- Butterweck, V., Peterleit, F., Winterhoff, H., Nahrstedt, A. (1998) Solubilized hypericin and pseudohypericin from *Hypericum perforatum* exert antidepressant activity in the forced swimming test. *Planta Med.* 64: 291–294
- Chi, J. D., Franklin, M. (1999) Measurement of hyperforin a constituent of St. John's wort in plasma by high-performance liquid chromatography. *J. Chromatogr. B. Biomed. Sci. Appl.* 735: 285–288
- Cos, P., Calomme, M., Sindambiwe, J. B., De Brune, T., Cimanga, K., Pieters, L., Vlietinck, A. J., Vanden Berghe, D. (2001) Cytotoxicity and lipid peroxidation-inhibiting activity of flavonoids. *Planta Med.* 67: 515–519
- Csokay, B., Prajda, N., Weber, G., Olah, E. (1997) Molecular mechanisms in the antiproliferative action of quercetin. *Life Sci.* 60: 2157–2163
- Erdelmeier, C. A. (1998) Hyperforin, possibly the major non-nitrogenous secondary metabolite of *Hypericum perforatum* L. *Pharmacopsychiatry* 31 (Suppl.): 2–6
- Gurevich, A. I., Dobrynin, V. N., Kolosov, M. N., Popravko, S. A., Riabova, I. D. (1971) Antibiotic hyperforin from *Hypericum perforatum* L [Article in Russian]. *Antibiotiki* 16: 510–513
- Hostanska, K., Reichling, J., Bommer, S., Weber, M., Saller, R. (2002) Aqueous ethanolic extract of St. John's wort (*Hypericum perforatum* L.) induces growth inhibition and apoptosis in human malignant cells in vitro. *Pharmazie* 57: 323–331
- Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y., Ueno, K. (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly water soluble tetrazolium salt, neutral red and crystal violet. *Biol. Pharm. Bull.* 11: 1518–1520
- Jia, L., Patwari, Y., Srinivasula, S. M., Newland, A. C., Fernandes-Alnemri, T., Alnemri, E. S., Kelsey, S. M. (2001) Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. *Oncogene* 20: 4817–4826
- Jurgenliemk, Q., Nahrstedt, A. (2002) Phenolic compounds from *Hypericum perforatum*. *Planta Med.* 68: 88–91
- Kang, T. B., Liang, N. C. (1997) Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. *Biochem. Pharmacol.* 54: 1013–1018
- Lavie, G., Kaplinsky, C., Toren, A., Aizman, I., Meruelo, D., Mazur, Y., Mandel, M. (1999) A photodynamic pathway to apoptosis and necrosis induced by dimethyltetrahydroxyhelianthron and hypericin in leukemic cells: possible relevance to photodynamic therapy. *Br. J. Cancer* 79: 423–432
- Maisenbacher, P., Kovar, K. A. (1992) Adhyperforin: A homologue of hyperforin from *Hypericum perforatum*. *Planta Med.* 58: 291–293
- Meier, B. (1999) Vergleichbarkeit von Phytopharmaka am Beispiel von Johanniskraut. In: Loew, D., Blume, H., Dingermann, T. (eds) *Phytopharmaka V, Forschung und klinische Anwendung*. Steinkopf, Darmstadt, pp. 51–61
- Miccoli, L., Beurdeley-Thomas, A., De Pinieux, G., Sureau, F., Oudard, S., Dutrillaux, B., Poupon, M.-F. (1998) Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. *Cancer Res.* 58: 5777–5786
- Mirossay, A., Onderkova, H., Mirossay, L., Sarisky, M., Mojzis, J. (2001) The effect of quercetin on light-induced cytotoxicity of hypericin. *Physiol. Res.* 50: 635–637
- Nagao, T., Abe, F., Okabe, H. (2001) Antiproliferative constituents in the plants 7. Leaves of *Clerodendron bungei* and leaves and bark of *C. trichotomum*. *Biol. Pharm. Bull.* 24: 1338–1341
- Noldner, M., Schotz, K. (2002) Rutin is essential for the antidepressant activity of *Hypericum perforatum* extracts in the forced swimming test. *Planta Med.* 68: 577–580
- Orth, H. C., Rentel, C., Schmidt, P. C. (1999) Isolation, purity analysis and stability of hyperforin as a standard material from *Hypericum perforatum* L. *J. Pharm. Pharmacol.* 51: 193–200
- Rong, Y., Yang, E. B., Zhang, K., Mack, P. (2000) Quercetin-induced apoptosis in the monoblastoid cell line U937 in vitro and the regulation of heat shock proteins expression. *Anticancer Res.* 20: 4339–4345
- Rücker, G., Manns, D., Hartmann, R., Bonsels, U. (1995) Peroxides as constituents of plants. 19.A C(50)-hydroperoxide from *Hypericum perforatum*. *Arch. Pharm. (Weinheim)* 328: 725–730
- Schempp, C. M., Winghofer, B., Ludtke, R., Simon-Haarhaus, B., Schopf, E., Simom, J. C. (2000) Topical application of St John's wort (*Hypericum perforatum* L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. *Br. J. Dermatol.* 142: 979–984
- Schempp, C. M., Kirkin, V., Simon-Haarhaus, B., Kersten, A., Kiss, J., Termeer, C. C., Gilb, B., Kaufmann, T., Borner, C., Sleeman, J. P., Simon, J. C. (2002) Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. *Oncogene* 21: 1242–1250
- Silva, G. L., Chai, H., Gupta, M. P., Farnsworth, N. R., Cordell, G. A., Pezzuto, J. M., Beecher, C. W., Kinghorn, A. D. (1995) Cytotoxic bioflavonoids from *Selaginella willdenowii*. *Phytochemistry* 40: 129–134
- Tekelova, D., Repcak, M., Zemkova, E., Toth, J. (2000) Quantitative changes of dianthrones, hyperforin and flavonoids content in the flower ontogenesis of *Hypericum perforatum*. *Planta Med.* 66: 778–780
- Uddin, S., Choudhry, M. A. (1995) Quercetin, a bioflavonoid, inhibits the DNA synthesis of human leukemia cells. *Biochem. Mol. Biol. Int.* 36: 545–550
- Wilhelm, K. P., Biel, S., Siegers, C. P. (2001) Role of flavonoids in controlling the phototoxicity of *Hypericum perforatum* extracts. *Phytomedicine* 8: 306–309
- Zheng, Z. S., Xue, G. Z., Grunberger, D., Prystowsky, J. H. (1995) Caffeic acid phenethyl ester inhibits proliferation of human keratinocytes and interferes with the EGF regulation of ornithine decarboxylase. *Oncol. Res.* 7: 445–452